The new facility, in Veenendaal, the Netherlands, houses six dedicated clean rooms that can work with up to 1kg of highly-potent active pharmaceutical ingredient (HPAPI) each.
The Indian contract manufacturer said that the new lab will help it build both HPAPI and vitamin D analog production capacity, which it added is a key part of its growth strategy.
Dishman added that the US Food and Drug Administration (FDA) is expected to begin current good manufacturing practice (cGMP) assessment early next year with full operations scheduled to start before the end of 2010.